left-arrow right-arrow pinterest facebook google_plus linkedin

Alliance A021602

Status:

Recruiting | Phase III

Official Title:

Testing cabozantinib in patients with advanced pancreatic neuroendocrine and carcinoid tumors after progression on everolimus.

Study Purpose:

The purpose of this study is to learn if treatment with a drug called cabozantinib to prevent tumor growth is better, the same, or worse than placebo (a pill that contains no active drug).

Interventions:

  • Group 1 will take cabozantinib tablets by mouth once daily.
  • Group 2 will take placebo tablets by mouth once daily.
  • Quality of life questionnaires
  • Optional blood and tissue collection for known and unknown future research.

Patients that have cancer growth will be followed every 6 months for survival until 8 years after starting the study. If therapy is discontinued for reasons other than cancer growth, exams and imaging should be performed every 12 weeks until your cancer grows or start of a new cancer treatment.

Key Participation Requirements:

Gender:

Male or Female

Age:

19 years and older

Diagnosis:

Neuroendocrine tumors of the pancreas and carcinoid tumors of the GI tract, lung, or other carcinoid tumors.

Eligibility:

Must have had at least one prior therapy that included the drug everolimus.

Disease cannot be surgically resectable.

Patients must sign an approved informed consent and authorization permitting release of personal health information.

Methodist Health System Trial Code:

Alliance A021602

For more information, visit the U.S. National Library of Medicine clinical trial database.

To learn more about this clinical trial please contact us today!